ANAPTYSBIO, INC
Congressional Trades
No congressional trades in ANAB on record.
Whale Activity
- Increased88
- New45
- Held25
- Decreased60
- Closed33
- No prior filing10
| Filer | Shares | Value | Change |
|---|---|---|---|
| EcoR1 Capital, LLC | 7.9M | $396.1M | held |
| BlackRock, Inc. | 1.9M | $95.1M | increased |
| TANG CAPITAL MANAGEMENT LLC | 1.5M | $74.1M | increased |
| STATE STREET CORP | 1.1M | $57.6M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 909.9K | $45.7M | increased |
| GOLDMAN SACHS GROUP INC | 850.3K | $42.7M | increased |
| Sanofi | 821.9K | $41.3M | held |
| D. E. Shaw & Co., Inc. | 819.6K | $41.2M | increased |
| MILLENNIUM MANAGEMENT LLC | 784.6K | $39.4M | decreased |
| 683 Capital Management, LLC | 740.0K | $37.2M | increased |
| CITADEL ADVISORS LLC | 650.6K | $32.7M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 639.7K | $32.2M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC / NODELMAN OLEGDirector · Director | Purchase | +138.1K | $46.54 | $6.4M | Nov 18, 2026 | Form 4 ↗ |
| EcoR1 Capital, LLC / NODELMAN OLEGDirector · Director | Purchase | +152.4K | $45.66 | $7.0M | Nov 17, 2026 | Form 4 ↗ |
| EcoR1 Capital, LLC / NODELMAN OLEGDirector · Director | Purchase | +84.1K | $45.66 | $3.8M | Nov 16, 2026 | Form 4 ↗ |
| RENTON HOLLINGSDirector · Director | Sale | −5,000 | $49.87 | $249K | Oct 1, 2026 | Form 4 ↗ |
| Orwin John ADirector | Option exercise | +1,300 | $0.00 | $0 | Sep 15, 2026 | Form 4 ↗ |
| Schmid John P.Director | Option exercise | +6,030 | $0.00 | $0 | Jun 15, 2026 | Form 4 ↗ |
| Orwin John ADirector | Option exercise | +6,030 | $0.00 | $0 | Jun 15, 2026 | Form 4 ↗ |
| RENTON HOLLINGSDirector | Option exercise | +6,030 | $0.00 | $0 | Jun 15, 2026 | Form 4 ↗ |
| Schmid John P.Director | Sale | −522 | $57.40 | $30K | Mar 30, 2026 | Form 4 ↗ |
| Schmid John P.Director | Sale | −7,527 | $56.70 | $427K | Mar 30, 2026 | Form 4 ↗ |
| Schmid John P.Director | Sale | −12.6K | $55.71 | $702K | Mar 30, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −100 | $65.99 | $7K | Mar 27, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −3,038 | $65.20 | $198K | Mar 27, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −3,155 | $64.19 | $203K | Mar 27, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −2,592 | $63.35 | $164K | Mar 27, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −1,012 | $62.15 | $63K | Mar 27, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −550 | $60.63 | $33K | Mar 27, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −490 | $59.62 | $29K | Mar 27, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −3,662 | $58.62 | $215K | Mar 27, 2026 | Form 4 ↗ |
| Faga DanielPresident, CEO · Director | Sale | −2,570 | $57.91 | $149K | Mar 27, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 786.6K | $53.1M | 0.49% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 648.1K | $43.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 514.9K | $34.8M | 0.04% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 237.0K | $16.0M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 263.8K | $14.1M | 0.35% | Jul 31, 2026 |
| iShares Biotechnology ETF iShares Trust | 193.5K | $13.1M | 0.14% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 185.5K | $12.5M | 0.08% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 215.9K | $11.5M | 0.03% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund Federated Hermes Equity Funds | 210.0K | $11.2M | 0.39% | Jul 31, 2026 |
| Victory Science & Technology Fund Victory Portfolios III | 187.9K | $10.0M | 0.67% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ANAB's shares (CUSIP 032724106), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- EcoR1 Capital Fund Qualified, L.P.SCHEDULE 13D/A · activist (13D) · 7.6M shares25.7%
Nov 18, 2026 · ↗ - Oleg NodelmanSCHEDULE 13D/A · activist (13D) · 8.3M shares27.8%
Nov 18, 2026 · ↗ - EcoR1 Capital, LLCSCHEDULE 13D/A · activist (13D) · 8.3M shares27.8%
Nov 18, 2026 · ↗ - Alex SilversteinSCHEDULE 13G/A · passive (13G) · 924.6K shares3.1%
Nov 16, 2026 · ↗ - Sirenia Capital Management LPSCHEDULE 13G/A · passive (13G) · 924.6K shares3.1%
Nov 16, 2026 · ↗ - Alex SilversteinSCHEDULE 13G/A · passive (13G) · 1.5M shares5.0%
Aug 14, 2026 · ↗ - Sirenia Capital Management LPSCHEDULE 13G/A · passive (13G) · 1.5M shares5.0%
Aug 14, 2026 · ↗ - Steven A. CohenSCHEDULE 13G/A · passive (13G) · 55.3K shares0.2%
May 15, 2026 · ↗ - Point72 Capital Advisors, Inc.SCHEDULE 13G/A · passive (13G) · 55.3K shares0.2%
May 15, 2026 · ↗ - Point72 Asset Management, L.P.SCHEDULE 13G/A · passive (13G) · 55.3K shares0.2%
May 15, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming ANAPTYSBIO, INC as the client.
Government Contracts
No federal contract awards found for ANAPTYSBIO, INC.
U.S. Patents
No USPTO patent applications found for ANAPTYSBIO, INC.
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M | -$56.8M |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M | -$57.8M |
| Diluted EPS | -$0.46 | -$5.12 | -$6.08 | -$4.57 | -$2.11 |
| Operating cash flow | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M |
| Cash and equivalents | $238.2M | $123.1M | $36.0M | $71.3M | $495.7M |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M |
| Shareholders' equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M |
As ANAPTYSBIO, INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 3, 2026 ↗
Stock Splits
- 3-for-2Stock splitApr 20, 2026
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
EDGAR ↗ - 8-K · Items 9.01Sep 21, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteAug 11, 2026
EDGAR ↗ - 8-K · Items 7.01Reg FD disclosureJul 30, 2026
EDGAR ↗ - 8-K · Items 1.01Material agreementJun 22, 2026
EDGAR ↗ - 8-K · Items 7.01Reg FD disclosureMay 29, 2026
EDGAR ↗ - 8-K · Items 5.03Bylaw amendmentMay 21, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 12, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeMay 11, 2026
EDGAR ↗
